Want to see CRVO full AI Analyst Report?
CRVO Stock Chart & Stats
$3.98
-$0.11(-4.76%)
At close: 4:00 PM EST
$3.98
-$0.11(-4.76%)
Day’s Range― - ―
52-Week Range$2.13 - $13.13
Previous CloseN/A
Volume72.82K
Average Volume (3M)112.80K
Market Cap
$50.59M
Enterprise Value$27.33M
Total Cash (Recent Filing)$12.92M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.16
Next Earnings
Aug 17, 2026EPS Estimate
-0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.27
Shares Outstanding13,526,233
10 Day Avg. Volume143,994
30 Day Avg. Volume112,798
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)3.92
Price to Sales (P/S)0.00
P/FCF Ratio-3.05
Enterprise Value/Market Cap0.54
Enterprise Value/Revenue84.74
Enterprise Value/Gross Profit84.74
Enterprise Value/Ebitda-0.91
Forecast
1Y Price Target
$20.40Price Target Upside412.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.7
Revenue Forecast (FY)$228.57K
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressCompleting Phase 2a enrollment and securing biomarker presentation represents durable de-risking of the lead program: fixed trial execution reduces operational uncertainty, enables upcoming objective readouts that can unlock partnerships or registrational planning, and diversifies pipeline evidence beyond DLB.
Strengthened Intellectual PropertyA granted patent extending protection into 2042 materially enhances long-term exclusivity for neflamapimod in a defined DLB population. Stronger IP supports partner negotiations, preserves future commercial optionality, and raises the strategic value of clinical success over multi-year horizons.
Clean Leverage And Financing AccessA debt-free balance sheet reduces solvency risk and interest burdens, while demonstrated success in raising equity capital and structured placements shows the company can access markets and institutional support. This preserves operational flexibility to pursue mid-stage milestones over coming quarters.
Bears Say
Minimal And Declining RevenuePersistently minimal and falling revenue underscores that CervoMed remains pre-commercial with no recurring product sales. This diminishes internal funding ability, increases dependency on external capital, and means long-term value hinges entirely on clinical and regulatory outcomes rather than ongoing cash generation.
High Cash Burn And Limited RunwaySustained negative operating cash flow and a sharply declining cash balance create structural execution risk: the business needs repeated financings to sustain trials, which can dilute shareholders and complicate long-term planning if capital markets tighten before key readouts or partnership monetization.
Large Losses And Declining EquitySubstantial recurring losses and rapidly shrinking equity weaken balance-sheet resilience over time, limiting strategic optionality. Eroding assets reduce the company's buffer against adverse outcomes, heighten refinancing needs, and can impede ability to fund larger, more expensive Phase 3 programs without significant external support.
CervoMed News
CRVO FAQ
What was CervoMed’s price range in the past 12 months?
CervoMed lowest stock price was $2.13 and its highest was $13.13 in the past 12 months.
What is CervoMed’s market cap?
CervoMed’s market cap is $50.59M.
When is CervoMed’s upcoming earnings report date?
CervoMed’s upcoming earnings report date is Aug 17, 2026 which is in 37 days.
How were CervoMed’s earnings last quarter?
CervoMed released its earnings results on May 18, 2026. The company reported -$0.86 earnings per share for the quarter, missing the consensus estimate of -$0.786 by -$0.074.
Is CervoMed overvalued?
According to Wall Street analysts CervoMed’s price is currently Undervalued.
Does CervoMed pay dividends?
CervoMed does not currently pay dividends.
What is CervoMed’s EPS estimate?
CervoMed’s EPS estimate is -0.8.
How many shares outstanding does CervoMed have?
CervoMed has 13,526,233 shares outstanding.
What happened to CervoMed’s price movement after its last earnings report?
CervoMed reported an EPS of -$0.86 in its last earnings report, missing expectations of -$0.786. Following the earnings report the stock price went down -11.628%.
Which hedge fund is a major shareholder of CervoMed?
Currently, no hedge funds are holding shares in CRVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CervoMed Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.40 (412.56% Upside)
$20.40 (412.56% Upside)
Hedge Fund Trend
Decreased
By 74.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 22.3%
Last 30 Days ▲ 22.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-49.60%
12-Months-Change
Fundamentals
Return on Equity
-136.08%
Trailing 12-Months
Asset Growth
-60.82%
Trailing 12-Months
Company Description
CervoMed
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
CRVO Stock 12 Month Forecast
Average Price Target
$20.40
▲(412.56% Upside)
Technical Analysis
X4 Pharmaceuticals
―
ABVC BioPharma
―
Jasper Therapeutics
―
Prelude Therapeutics
―
Estrella Immunopharma
―
Ownership Overview
37.22% Insiders
2.74% Mutual Funds
0.38% Other Institutional Investors
57.15% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---